This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
OncoGenex Pharmaceuticals, Inc.
Drug Names(s): CRPC 1L, ISIS 112989, OGX-011, TV-1011, Custirsen Sodium
Description: OGX-011 is an antisense construct being developed as a chemo- and radiosensitizer. It inhibits the biological activity of clusterin, a protein that makes tumors resistant to conventional treatment. Clusterin is overexpressed in multiple solid tumor types that the companies hope will serve as additional indications for OGX-011’s use.
Revenue splits for this drug are BioMedTracker estimates.
On November 26, 2001, Isis and OncoGenex partnered to develop OGX-011.
OncoGenex and Sonus
In May 2008, Sonus Pharmaceuticals and OncoGenex Technologies jointly announced the signing of a definitive agreement to merge the two companies. The combined company will operate as OncoGenex Pharmaceuticals.
Under the terms of the proposed merger, OncoGenex' stock and debenture holders will receive approximately 37 million shares of Sonus common stock and OncoGenex will become a wholly owned subsidiary of Sonus Pharmaceuticals. Following the close of the proposed transaction, OncoGenex stockholders will hold 50% of Sonus' outstanding shares of common stock. An additional 25 million shares will be held in escrow and released to OncoGenex' shareholders upon achievement of specific milestones that are intended to demonstrate continued development of OncoGenex' assets and execution of the combined...See full deal structure in Biomedtracker
Partners: Ionis Pharmaceuticals, Inc.
Additional information available to subscribers only: